Induced Pluripotent Stem Cells Developed to Provide Improved Model Fidelity

AMSBIO has introduced a cutting-edge range of genetically engineered Induced Pluripotent Stem Cells (iPSCs), designed to enhance model fidelity in drug discovery and cell therapy research. These advanced iPSC cell lines provide significant efficiency and cost savings over traditional animal models, making them ideal for high-throughput reporter lines, human disease models, and toxicity screening. The new offerings include iPSCs engineered to express Cas9, either constitutively or via doxycycline induction (tet-on), enabling precise gene editing to create knockout, mutated, or knock-in cells.

A highlight of this range is the B2M Knockout iPS cell line, which retains the full functional capacity of iPSCs while exhibiting extremely low immunogenicity, making it a valuable tool for allogeneic cell therapy research. Additionally, the StemBright™ Reporter iPSCs are engineered to express conditional reporter genes, responding to transcription factor activation or constitutively expressing luciferase or eGFP for cell tracking.

AMSBIO also offers custom iPSC services, including the design of engineered iPSCs, large-scale cell differentiation, and compound screening on iPSCs or differentiated cells, providing researchers with tailored solutions to accelerate their studies.